| The shieldin complex mediates 53BP1-dependent DNA repair SM Noordermeer, S Adam, D Setiaputra, M Barazas, SJ Pettitt, AK Ling, ... Nature 560 (7716), 117-121, 2018 | 592 | 2018 |
| Agouti C57BL/6N embryonic stem cells for mouse genetic resources SJ Pettitt, Q Liang, XY Rairdan, JL Moran, HM Prosser, DR Beier, ... Nature methods 6 (7), 493-495, 2009 | 453 | 2009 |
| Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance SJ Pettitt, DB Krastev, I Brandsma, A Dréan, F Song, R Aleksandrov, ... Nature communications 9 (1), 1849, 2018 | 406 | 2018 |
| PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer RM Chabanon, G Muirhead, DB Krastev, J Adam, D Morel, M Garrido, ... The Journal of clinical investigation 129 (3), 1211-1228, 2019 | 294 | 2019 |
| Structural basis for allosteric PARP-1 retention on DNA breaks L Zandarashvili, MF Langelier, UK Velagapudi, MA Hancock, JD Steffen, ... Science 368 (6486), eaax6367, 2020 | 279 | 2020 |
| Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance D Zatreanu, HMR Robinson, O Alkhatib, M Boursier, H Finch, L Geo, ... Nature communications 12 (1), 3636, 2021 | 252 | 2021 |
| Phase I trial of first-in-class ATR inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors TA Yap, B O’Carrigan, MS Penney, JS Lim, JS Brown, ... Journal of Clinical Oncology 38 (27), 3195-3204, 2020 | 206 | 2020 |
| A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity SJ Pettitt, FL Rehman, I Bajrami, R Brough, F Wallberg, I Kozarewa, ... PloS one 8 (4), e61520, 2013 | 193 | 2013 |
| The CST complex mediates end protection at double-strand breaks and promotes PARP inhibitor sensitivity in BRCA1-deficient cells M Barazas, S Annunziato, SJ Pettitt, I de Krijger, H Ghezraoui, SJ Roobol, ... Cell reports 23 (7), 2107-2118, 2018 | 152 | 2018 |
| Clinical BRCA1/2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance SJ Pettitt, JR Frankum, M Punta, S Lise, J Alexander, Y Chen, TA Yap, ... Cancer discovery 10 (10), 1475-1488, 2020 | 142 | 2020 |
| E-cadherin/ROS1 inhibitor synthetic lethality in breast cancer I Bajrami, R Marlow, M van de Ven, R Brough, HN Pemberton, J Frankum, ... Cancer discovery 8 (4), 498-515, 2018 | 118 | 2018 |
| Biomarkers associating with PARP inhibitor benefit in prostate cancer in the TOPARP-B trial S Carreira, N Porta, S Arce-Gallego, G Seed, A Llop-Guevara, D Bianchini, ... Cancer discovery 11 (11), 2812-2827, 2021 | 114 | 2021 |
| Defective ALC1 nucleosome remodeling confers PARPi sensitization and synthetic lethality with HRD G Hewitt, V Borel, S Segura-Bayona, T Takaki, P Ruis, R Bellelli, ... Molecular cell 81 (4), 767-783. e11, 2021 | 113 | 2021 |
| HNF4A and GATA6 loss reveals therapeutically actionable subtypes in pancreatic cancer H Brunton, G Caligiuri, R Cunningham, R Upstill-Goddard, UM Bailey, ... Cell reports 31 (6), 2020 | 108 | 2020 |
| Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells J Nikkilä, R Kumar, J Campbell, I Brandsma, HN Pemberton, F Wallberg, ... British journal of cancer 117 (1), 113-123, 2017 | 105 | 2017 |
| The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin DB Krastev, S Li, Y Sun, AJ Wicks, G Hoslett, D Weekes, LM Badder, ... Nature cell biology 24 (1), 62-73, 2022 | 104 | 2022 |
| The piggyBac transposon displays local and distant reintegration preferences and can cause mutations at noncanonical integration sites MA Li, SJ Pettitt, S Eckert, Z Ning, S Rice, J Cadiñanos, K Yusa, N Conte, ... Molecular and cellular biology, 2013 | 101 | 2013 |
| Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non–BRCA1/2-Mutant Cancers TA Yap, R Kristeleit, V Michalarea, SJ Pettitt, JSJ Lim, S Carreira, D Roda, ... Cancer discovery 10 (10), 1528-1543, 2020 | 100 | 2020 |
| PBRM1 deficiency confers synthetic lethality to DNA repair inhibitors in cancer RM Chabanon, D Morel, T Eychenne, L Colmet-Daage, I Bajrami, ... Cancer research 81 (11), 2888-2902, 2021 | 86 | 2021 |
| Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer K Van Baelen, T Geukens, M Maetens, V Tjan-Heijnen, CJ Lord, S Linn, ... Annals of Oncology 33 (8), 769-785, 2022 | 75 | 2022 |
